MedTrace Logo

Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma

NCT04735861 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2024-08-13

No results posted yet for this study

Summary

Ovarian clear cell carcinoma (OCCC) is one of the rare subtypes of ovarian cancer, yet its prognosis is extremely poor. Previous studies indicate that both bevacizumab and PD-1 inhibitor have clinical benefits for OCCC patients. And the combination of bevacizumab and PD-1 inhibitor has shown preliminary safety and clinical activity. Therefore, this study aims to investigate the potential benefit of combination therapy for patients with OCCC.

Conditions

Interventions

DRUG

Sintilimab

Sintilimab 200mg iv. q3w, up to 2 years.

DRUG

Bevacizumab Biosimilar IBI305

Bevacizumab 15mg/kg iv. q3w, up to 22 cycles

Sponsors & Collaborators

  • Union Hospital affiliated to Tongji Medical College

    collaborator UNKNOWN

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • Henan Cancer Hospital

    collaborator OTHER_GOV

  • Hubei Cancer Hospital

    collaborator OTHER

  • Shengjing Hospital

    collaborator OTHER

  • Anhui Provincial Cancer Hospital

    collaborator OTHER

  • Zhongnan Hospital

    collaborator OTHER

  • Jingzhou Central Hospital

    collaborator OTHER

  • The First People's Hospital of Jingzhou

    collaborator OTHER

  • Xiangyang Central Hospital

    collaborator OTHER

  • Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital

    collaborator UNKNOWN

  • Tongji Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-07
Primary Completion
2024-07-30
Completion
2024-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04735861 on ClinicalTrials.gov